<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>334</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11525169</PubmedId>
            <Abstract>BACKGROUND: CD40 ligand (CD40L or CD154), a member of the tumor necrosis factor (TNF) family, plays a critical role in both humoral and cellular immune responses and has been implicated in biological pathways involving epithelial cells, fibroblasts, and platelets. Such a pathway is T cell-mediated B cell activation, a process that occurs through the interaction of CD40L with CD40 receptor expressed on B cells. It results in various B cell responses, including immunoglobulin isotype switching and B cell differentiation and proliferation. These responses can be inhibited by the monoclonal antibody 5c8, which binds with high affinity to CD40L. RESULTS: CD40 ligand (CD40L or CD154), a member of the tumor necrosis factor (TNF) family, plays a critical role in both humoral and cellular immune responses and has been implicated in biological pathways involving epithelial cells, fibroblasts, and platelets. Such a pathway is T cell-mediated B cell activation, a process that occurs through the interaction of CD40L with CD40 receptor expressed on B cells. It results in various B cell responses, including immunoglobulin isotype switching and B cell differentiation and proliferation. These responses can be inhibited by the monoclonal antibody 5c8, which binds with high affinity to CD40L.To understand the structural basis of the inhibition, we determined the crystal structure of the complex of the extracellular domain of CD40L and the Fab fragment of humanized 5c8 antibody. The structure shows that the complex has the shape of a three-bladed propeller with three Fab fragments bound symmetrically to a CD40L homotrimer. To further study the nature of the antibody-antigen interface, we assessed the ability of 23 site-directed mutants of CD40L to bind to 5c8 and CD40 and analyzed the results in the context of the crystal structure. Finally, we observed via confocal microscopy that 5c8 binding to CD40L on the cell surface results in the formation of patches of clustered complexes. CONCLUSIONS: CD40 ligand (CD40L or CD154), a member of the tumor necrosis factor (TNF) family, plays a critical role in both humoral and cellular immune responses and has been implicated in biological pathways involving epithelial cells, fibroblasts, and platelets. Such a pathway is T cell-mediated B cell activation, a process that occurs through the interaction of CD40L with CD40 receptor expressed on B cells. It results in various B cell responses, including immunoglobulin isotype switching and B cell differentiation and proliferation. These responses can be inhibited by the monoclonal antibody 5c8, which binds with high affinity to CD40L.To understand the structural basis of the inhibition, we determined the crystal structure of the complex of the extracellular domain of CD40L and the Fab fragment of humanized 5c8 antibody. The structure shows that the complex has the shape of a three-bladed propeller with three Fab fragments bound symmetrically to a CD40L homotrimer. To further study the nature of the antibody-antigen interface, we assessed the ability of 23 site-directed mutants of CD40L to bind to 5c8 and CD40 and analyzed the results in the context of the crystal structure. Finally, we observed via confocal microscopy that 5c8 binding to CD40L on the cell surface results in the formation of patches of clustered complexes.The structure reveals that 5c8 neutralizes CD40L function by sterically blocking CD40 binding. The antigenic epitope is localized in a region of the surface that is likely to be structurally perturbed as a result of genetic mutations that cause hyper-IgM syndrome. The symmetric trimeric arrangement of the Fab fragments in the complex results in a geometry that facilitates the formation of large clusters of complexes on the cell surface.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>321-9</ArticlePages>
            <ArticleTitle>Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Karpusas</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Lucci</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Ferrant</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Benjamin</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>F R</ForeName>
                </Author>
                <Author>
                    <LastName>Strauch</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Garber</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Hsu</LastName>
                    <ForeName>Y M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Biogen, Inc,  Cambridge, Massachusetts 02142, USA. michael_karpusas@biogen.com.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Epitopes;Immunoglobulin Fab Fragments;CD40 Ligand</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(chemistry; immunology); Antibody Affinity; Binding Sites, Antibody; CD40 Ligand(chemistry; genetics; immunology); Crystallography, X-Ray; Epitopes(chemistry; genetics; immunology); Humans; Immunoglobulin Fab Fragments(chemistry; immunology); Mice; Microscopy, Confocal; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Neutralization Tests; Protein Conformation; Static Electricity</ArticleMeshHeadingsList>
            <Journal>
                <Volume>9</Volume>
                <Issue>4</Issue>
                <Title>Structure (London, England : 1993)</Title>
                <Issn>1878-4186</Issn>
                <MedlineTa>Structure</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>humanized mAb 5c8 epitope on CD40L extracellular domain</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>E129, A130, S132, E142, K143, G144, Y146, C178, C218, S245, Q246, S248, H249, G250</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P29965.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 4 and PDB 1I9R</LocationOfData>
                <EpitopeId>77425</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 2, 4 and PDB 1I9R</LocationOfData>
                        <BCellId>1491562</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>D1.1 cells</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>6 doses of 2x10^6 cells 2 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the cited reference: Lederman et al. (1992) J Exp Med 175(4): 1091-1101 [PMID: 1348081]. Mice were immunized with 2 x 10&lt;sup&gt;6&lt;/sup&gt; Jurkat D1.1 cells in saline intravenously and then boosted intraperitoneally at five ~2-wk intervals. One mouse was boosted with the same dose of D1.1 cells i.v.. 3 days before cell fusion of splenocytes with SP2/0 myeloma cells. The mouse mAb 5c8 (IgG2a) was humanized by cloning into a human IgG1 framework.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.1</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of humanized antibody 5c8 Fab on the extracellular domain of CD40 ligand was determined from the crystal structure of the complex, solved by molecular replacement. The asymmetric unit of the crystal contains a single complex consisting of a CD40L homotrimer and three Fab fragments.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>humanized 5c8</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Humanized 5c8</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1I9R_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1I9R_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P29965.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1I9R</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>A</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Details of antigen-antibody contacts are not provided in the paper. The antibody is using CDR H1, CDR H2, and CDR H3 hypervariable regions as well as CDR L1 and CDR L3 to form contacts with CD40L. A zinc ion located near the binding site has no direct contacts with CD40L, and is not likely to play a functional role; its presence is probably a crystallization artifact. Comparing the free antigen structure [PDB:1ALY] with the Fab-CD40L complex showed no conformational changes for antigen upon antibody binding.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>A: E129, A130, S132, E142, K143, G144, Y146, C178, C218, S245, Q246, S248, H249, G250;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S31:CDRH1, Y32:CDRH1, Y33:CDRH1, N52:CDRH2, S54:CDRH2, N55:CDRH2, D57:CDRH2, N59:CDRH2, R102:CDRH3, N103:CDRH3; L: S31:CDRL1, S32:CDRL1, Y36:CDRL1, S95:CDRL3, W96:CDRL3;</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>771.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>765.0</ContactAreaForAntibody>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>A: E129, A130, S132, A141, E142, K143, G144, Y146, C178, S179, P217, C218, S245, Q246, S248, H249, G250, T251</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S31, Y32, Y33, N52, S54, N55, G56, D57, N59, G101, R102, N103; L: S31, S32, Y36, S95, W96, I98</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>732.1</ContactAreaForAntigen>
                                <ContactAreaForAntibody>723.1</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>3001533</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>D1.1 cells</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>6 doses of 2x10^6 cells 2 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the cited reference: Lederman et al. (1992) J Exp Med 175(4): 1091-1101 [PMID: 1348081]. Mice were immunized with 2 x 10&lt;sup&gt;6&lt;/sup&gt; Jurkat D1.1 cells in saline intravenously and then boosted intraperitoneally at five ~2-wk intervals. One mouse was boosted with the same dose of D1.1 cells i.v.. 3 days before cell fusion of splenocytes with SP2/0 myeloma cells. The mouse mAb 5c8 (IgG2a) was humanized by cloning into a human IgG1 framework.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific humanized 5c8 mAb immunoprecipitated CD40L. Mutational analysis was used to determine residues important for mAb 5c8 binding to CD40L. Mutations of contact residues E129G, K143A, H249A, abolished or reduced 5c8 binding. Some of the residues identified  (A123, V126, W140, L155, Y170, A235, T254, and G257) were not direct contacts but are involved in structural stabilization.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>humanized 5c8</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Humanized 5c8</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1I9R_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1I9R_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P29965.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1499305</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>D1.1 cells</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>6 doses of 2x10^6 cells 2 weeks apart</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the cited reference: Lederman et al. (1992) J Exp Med 175(4): 1091-1101 [PMID: 1348081]. Mice were immunized with 2 x 10&lt;sup&gt;6&lt;/sup&gt; Jurkat D1.1 cells in saline intravenously and then boosted intraperitoneally at five ~2-wk intervals. One mouse was boosted with the same dose of D1.1 cells i.v.. 3 days before cell fusion of splenocytes with SP2/0 myeloma cells. The mouse mAb 5c8 (IgG2a) was humanized by cloning into a human IgG1 framework.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb 5c8 recognized CD40 ligand on the surface of D1.1 cells by immunofluorescence confocal microscopy.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>humanized 5c8</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Humanized 5c8</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1I9R_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1I9R_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P29965.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <Cell>
                                    <SubType>Cell</SubType>
                                    <CellType>T cell</CellType>
                                    <CellTissueType>Blood</CellTissueType>
                                    <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                                    <CellSourceOrganismId>9606</CellSourceOrganismId>
                                </Cell>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

